NanoGhost wins sixth Israel Innovation Authority grant for immuno-oncology program with BGU
What's the deal? Israeli biotech NanoGhostDealroom has a profile for this one. Try Dealroom → has won a grant from the Israel Innovation AuthorityDealroom has a profile for this one. Try Dealroom → to fund an immuno-oncology research program with Ben-Gurion University of the Negev.
The program targets immune checkpoint inhibitors for hard-to-treat cancers, including brain tumours such as glioblastoma. It runs through the university's technology transfer company, BGNDealroom has a profile for this one. Try Dealroom →.
Why now? This is the sixth grant the authority has awarded NanoGhost, signalling continued confidence in its drug delivery platform.
The company builds nano-vesicles from mesenchymal stem cell membranes to deliver therapies straight to diseased tissue, aiming to boost efficacy while cutting toxicity.
To date, NanoGhost has raised roughly $17 million, including about $4.5 million in non-dilutive grants.
What could go wrong? The technology remains preclinical. Promising lab results do not guarantee success in human trials, and glioblastoma has defeated countless therapies.
Checkpoint inhibitors already exist, so NanoGhost must prove its targeted approach works where others fall short.
The signal: Repeated backing from the Israel Innovation Authority — now NanoGhost's sixth grant — underscores how state-backed funding fund vehicles continue to underwrite early-stage Israeli biotech through capital-intensive preclinical phases. For a company that has raised roughly $17 million, including about $4.5 million in non-dilutive grants, that public support is buying time to prove its stem-cell-derived delivery platform before private capital is required at scale.
Read more: einpresswire.com
Image credit: "HIV on Bridges Between Infected Immune Cell and Uninfected Brain Cell" by National Institutes of Health (NIH) is marked with Public Domain Mark 1.0. To view the terms, visit https://creativecommons.org/publicdomain/mark/1.0/.
